Equities research analysts forecast that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will announce earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for HTG Molecular Diagnostics’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.18). HTG Molecular Diagnostics posted earnings of ($0.46) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 58.7%. The firm is expected to issue its next earnings results on Tuesday, November 6th.
On average, analysts expect that HTG Molecular Diagnostics will report full-year earnings of ($0.71) per share for the current year, with EPS estimates ranging from ($0.79) to ($0.63). For the next financial year, analysts anticipate that the company will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.57) to ($0.48). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings data on Thursday, August 9th. The medical research company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. The company had revenue of $4.91 million for the quarter, compared to analysts’ expectations of $5.30 million. HTG Molecular Diagnostics had a negative net margin of 81.10% and a negative return on equity of 132.67%.
Shares of HTGM stock traded down $0.06 during trading on Thursday, hitting $3.36. The company had a trading volume of 264,400 shares, compared to its average volume of 1,146,911. The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35. The stock has a market cap of $101.75 million, a price-to-earnings ratio of -1.88 and a beta of 1.46. HTG Molecular Diagnostics has a 52 week low of $1.59 and a 52 week high of $5.83.
Institutional investors and hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund purchased a new stake in HTG Molecular Diagnostics in the first quarter worth approximately $170,000. Northern Trust Corp purchased a new stake in HTG Molecular Diagnostics in the first quarter worth approximately $189,000. BlackRock Inc. boosted its stake in HTG Molecular Diagnostics by 322.8% in the second quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock worth $238,000 after buying an additional 55,769 shares in the last quarter. Stifel Financial Corp purchased a new stake in HTG Molecular Diagnostics in the first quarter worth approximately $343,000. Finally, Acadian Asset Management LLC purchased a new stake in HTG Molecular Diagnostics in the second quarter worth approximately $353,000. 37.90% of the stock is owned by institutional investors and hedge funds.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Read More: Trading Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.